# Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment

> **NCT07282093** · PHASE1 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Pharmacokinetic
- Olverembatinib

## Interventions

- **DRUG:** Olverembatinib 20mg

## Key facts

- **NCT ID:** NCT07282093
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-10-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282093, "Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07282093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*